Jarrett Jennifer 4
4 · Damora Therapeutics, Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Damora (DMRA) CEO Jennifer Jarrett Receives 2.0M-Share Award
What Happened Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics (DMRA), was granted compensation awards on March 30, 2026: 500,000 restricted stock units (RSUs) and a derivative award representing the right to purchase 1,500,000 shares. Both grants were reported with an acquisition price of $0.00 (typical for equity awards); no shares were sold or purchased for cash in this filing.
Key Details
- Transaction date: March 30, 2026; Form 4 filed April 1, 2026 (appears timely — within typical two-business-day reporting window).
- Grants: 500,000 RSUs (non‑derivative) and a 1,500,000-share option/derivative award; both reported at $0.00.
- Vesting (per filing footnotes): RSUs vest 25% on each anniversary through the fourth anniversary of the grant date. The option vests 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030.
- Shares owned after the transaction: not specified in the information provided in this summary.
- Remarks: Reporting person is President and Chief Executive Officer. No 10b5-1, tax‑withholding sale, or late‑filing flag noted in the filing excerpt provided.
Context
- RSUs convert to actual shares only as they vest and are settled; the option award is a right to purchase shares subject to future vesting — neither represents immediately tradable shares upon grant.
- These awards are typical executive compensation and do not indicate an immediate buy or sell decision by the insider. They should be interpreted as future potential equity upside contingent on continued service and vesting conditions.
Insider Transaction Report
Form 4
Jarrett Jennifer
DirectorSee Remarks
Transactions
- Award
Common Stock
[F1]2026-03-30+500,000→ 500,000 total - Award
Stock Option (right to buy)
[F2]2026-03-30+1,500,000→ 1,500,000 totalExercise: $25.50Exp: 2036-03-30→ Common Stock (1,500,000 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F2]This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 30, 2027 and in equal monthly installments thereafter through March 30, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Signature
/s/ Garrett Winslow, attorney-in-fact|2026-04-01